Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

DAIICHI SANKYO, INC.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Other: Archival tissue specimen and immunohistochemistry staining

First Posted Date: 2023-03-15

Last Posted Date: 2023-04-10

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 225

Registration Number: NCT05769764

Locations: 🇺🇸
Baptist Health South Florida - Miami Cancer Institute, Miami, Florida, United States
🇺🇸
McLeod Health, Florence, South Carolina, United States

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumor
Breast Cancer

Interventions: Drug: DS-1103a
Drug: T-DXd

First Posted Date: 2023-03-13

Last Posted Date: 2025-05-11

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 78

Registration Number: NCT05765851

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Lifespan Cancer Institute, Providence, Rhode Island, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States

and more 5 locations

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: DS-7011a
Drug: Placebo

First Posted Date: 2022-12-06

Last Posted Date: 2025-04-04

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 26

Registration Number: NCT05638802

Locations: 🇺🇸
Pinnacle Research Group LLC, Anniston, Alabama, United States
🇺🇸
Arkansas Research Trials, North Little Rock, Arkansas, United States
🇺🇸
Office of Tory P. Sullivan, M.D. - North Miami Beach, North Miami Beach, Florida, United States

and more 9 locations

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

Phase 1

Completed

Conditions: Netherton Syndrome

Interventions: Drug: Placebo
Drug: DS-2325a

First Posted Date: 2022-10-18

Last Posted Date: 2023-05-18

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 24

Registration Number: NCT05583669

Locations: 🇺🇸
Quotient Sciences -Miami, Miami, Florida, United States

A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

Phase 2

Completed

Conditions: Pseudoxanthoma Elasticum

Interventions: Drug: DS-1211b
Other: Placebo

First Posted Date: 2022-10-06

Last Posted Date: 2024-12-31

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 65

Registration Number: NCT05569252

Locations: 🇺🇸
Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States
🇺🇸
Boston Neuro Research Center, North Dartmouth, Massachusetts, United States
🇺🇸
Infinity Medical Research Inc, North Dartmouth, Massachusetts, United States

and more 4 locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Phase 3

Recruiting

Conditions: Metastatic Non Small Cell Lung Cancer

Interventions: Drug: Datopotamab Deruxtecan
Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2022-09-27

Last Posted Date: 2025-06-26

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 1170

Registration Number: NCT05555732

Locations: 🇺🇸
Southern Cancer Center Pc, Daphne, Alabama, United States
🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸
Arizona Oncology Associates, Pc - Nahoa, Prescott Valley, Arizona, United States

and more 243 locations

A Dose Finding Study of VN-0200

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: VN-0200

First Posted Date: 2022-09-21

Last Posted Date: 2024-02-29

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 342

Registration Number: NCT05547087

Locations: 🇯🇵
SOUSEIKAI PS Clinic, Hakata, Fukuoka, Japan
🇯🇵
SOUSEIKAI Sumida Hopital, Sumida, Tokyo, Japan
🇯🇵
SOUSEIKAI Nishi-Kumamoto Hospital, Kumamoto, Japan

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

Completed

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Trastuzumab deruxtecan

First Posted Date: 2022-07-14

Last Posted Date: 2024-03-15

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 256

Registration Number: NCT05458401

Locations: 🇮🇪
St. Vincent's Private Hospital, Dublin, Ireland
🇮🇪
St. Vincent's University Hospital, Dublin, Ireland
🇮🇹
Breast Center Humanitas Cancer Center IRCCS Istituto Clinico Humanitas, Rozzano, Milano, Italy

and more 18 locations

A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Phase 4

Completed

Conditions: COPD Exacerbation Acute

Interventions: Drug: Sitafloxacin
Drug: Moxifloxacin Hydrochloride

First Posted Date: 2022-06-01

Last Posted Date: 2025-01-09

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 140

Registration Number: NCT05400369

Locations: 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, China
🇨🇳
The Sixth People's Hospital of Chengdu, Chengdu, China
🇨🇳
West China Hospital Sichuan University, Chengdu, China

and more 15 locations

A Study of DS-9606a in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Cancer
Metastatic Cancer
Ovarian Cancer
Germ Cell Tumor

Interventions: Drug: DS-9606a

First Posted Date: 2022-05-27

Last Posted Date: 2025-03-26

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 85

Registration Number: NCT05394675

Locations: 🇺🇸
SCRI at HealthONE, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists & Research Institute, LLC, Fort Myers, Florida, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy